Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A

Seeking AlphaJul 13 14:03 ET

Gilead Sciences's Options Frenzy: What You Need to Know

Deep-pocketed investors have adopted a bearish approach towards Gilead Sciences (NASDAQ:GILD), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga

BenzingaJul 11 15:48 ET

Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78

Gilead Sciences (GILD) has an average rating of outperform and price targets ranging from $67 to $119, according to analysts by Capital IQ.Price: 69.00, Change: +0.25, Percent Change: +0.36

MT NewswiresJul 11 08:40 ET

Morgan Stanley Maintains Gilead Sciences(GILD.US) With Hold Rating, Cuts Target Price to $74

Morgan Stanley analyst Terence Flynn maintains $Gilead Sciences(GILD.US)$ with a hold rating, and adjusts the target price from $78 to $74.According to TipRanks data, the analyst has a success rate

Moomoo NewsJul 11 08:34 ET · Ratings

Pfizer Signals Progress on Obesity Pill, Boosting Stock

By Ciara Linnane and Eleanor Laise Oral versions of popular weight-loss drugs could be cheaper, more accessible, analysts say Pfizer Inc.'s stock (PFE) rose 2.8% early Thursday, after the drug

MarketWatchJul 11 08:31 ET

Is Gilead Sciences (NASDAQ:GILD) A Risky Investment?

Yahoo FinanceJul 11 07:00 ET